Next Article in Journal / Special Issue
Reply to “Comment on López-Yerena et al. ‘Absorption and Intestinal Metabolic Profile of Oleocanthal in Rats’ Pharmaceutics 2020, 12, 134”
Previous Article in Journal
In Vivo Bactericidal Efficacy of GWH1 Antimicrobial Peptide Displayed on Protein Nanoparticles, a Potential Alternative to Antibiotics
Previous Article in Special Issue
Comment on López-Yerena et al. “Absorption and Intestinal Metabolic Profile of Oleocanthal in Rats” Pharmaceutics 2020, 12, 134
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: López-Yerena, A., et al. “Absorption and Intestinal Metabolic Profile of Oleocanthal in Rats” Pharmaceutics 2020, 12, 134

by
Anallely López-Yerena
1,
Anna Vallverdú-Queralt
1,2,
Raf Mols
3,
Patrick Augustijns
3,
Rosa M. Lamuela-Raventós
1,2 and
Elvira Escribano-Ferrer
2,4,*
1
Nutrition, Food Science and Gastronomy Department, XaRTA, Institute of Nutrition and Food Safety (INSA-UB), School of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain
2
CIBER Physiopathology of Obesity and Nutrition (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain
3
Drug Delivery and Disposition, KU Leuven, 3000 Leuven, Belgium
4
Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Biopharmaceutics and Pharmacokinetics Unit, Institute of Nanoscience and Nanotechnology (IN2UB), Pharmacy and Food Sciences School, University of Barcelona, 08028 Barcelona, Spain
*
Author to whom correspondence should be addressed.
Pharmaceutics 2020, 12(12), 1220; https://doi.org/10.3390/pharmaceutics12121220
Submission received: 25 November 2020 / Accepted: 8 December 2020 / Published: 17 December 2020
(This article belongs to the Special Issue Intestinal Drug Absorption)
The authors would like to make the following corrections to this paper [1]:

1. Change in Equation (1)

We have found two typographical errors in Equation (1) and we wish to replace
P eff = Ø in 2 π R L × L n   C in C out . cor
With
P eff = Ø in 2 π R L × L n   C out . cor C in

2. Change in Table 2

We have found a typographical error in the Peff heading in Table 2. In addition, and after reviewing the calculations again, we have detected that the data shown in Table 2 for levofloxacin did not consider the normalization of the 10-cm intestinal segment. With the normalization, the Peff value for levofloxacin increases (according to the length of the intestinal segment used). For these reasons, the authors wish to replace
Table 2. Permeability coefficients (Peff) and apparent permeability coefficients (Papp) of oleocanthal and levofloxacin. Results are expressed as the mean ± SD of n = 4. Data are normalised to a 10-cm intestinal segment.
Table 2. Permeability coefficients (Peff) and apparent permeability coefficients (Papp) of oleocanthal and levofloxacin. Results are expressed as the mean ± SD of n = 4. Data are normalised to a 10-cm intestinal segment.
Test CompoundPeff (×10−5 cm/s)Papp (×10−6 cm/s)
OLC2.23 ± 3.164.12 * ± 2.33
LEV7.64 ± 5.5510.91 ± 6.27
* p < 0.05, Mann-Whitney U-test.
With
Table 2. Permeability coefficients (Peff) and apparent permeability coefficients (Papp) of oleocanthal and levofloxacin. Results are expressed as the mean ± SD of n = 4. Data are normalised to a 10-cm intestinal segment.
Table 2. Permeability coefficients (Peff) and apparent permeability coefficients (Papp) of oleocanthal and levofloxacin. Results are expressed as the mean ± SD of n = 4. Data are normalised to a 10-cm intestinal segment.
Test CompoundPeff (×10−4 cm/s)Papp (×10−6 cm/s)
OLC2.85 ± 2.634.12 * ± 2.33
LEV12.69 ± 6.6410.91 ± 6.27
* p < 0.05, Mann–Whitney U-test.
These changes do not affect the discussion and conclusions of the study. The authors would like to apologize for any inconvenience caused to the readers by these changes.

Conflicts of Interest

R.M.L.-R. reports receiving lecture fees from Cerveceros de España and receiving lecture fees and travel support from Adventia. The other authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Reference

  1. López-Yerena, A.; Vallverdú-Queralt, A.; Mols, R.; Augustijns, P.; Lamuela-Raventós, R.M.; Escribano-Ferrer, E. Absorption and Intestinal Metabolic Profile of Oleocanthal in Rats. Pharmaceutics 2020, 12, 134. [Google Scholar] [CrossRef] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

López-Yerena, A.; Vallverdú-Queralt, A.; Mols, R.; Augustijns, P.; Lamuela-Raventós, R.M.; Escribano-Ferrer, E. Correction: López-Yerena, A., et al. “Absorption and Intestinal Metabolic Profile of Oleocanthal in Rats” Pharmaceutics 2020, 12, 134. Pharmaceutics 2020, 12, 1220. https://doi.org/10.3390/pharmaceutics12121220

AMA Style

López-Yerena A, Vallverdú-Queralt A, Mols R, Augustijns P, Lamuela-Raventós RM, Escribano-Ferrer E. Correction: López-Yerena, A., et al. “Absorption and Intestinal Metabolic Profile of Oleocanthal in Rats” Pharmaceutics 2020, 12, 134. Pharmaceutics. 2020; 12(12):1220. https://doi.org/10.3390/pharmaceutics12121220

Chicago/Turabian Style

López-Yerena, Anallely, Anna Vallverdú-Queralt, Raf Mols, Patrick Augustijns, Rosa M. Lamuela-Raventós, and Elvira Escribano-Ferrer. 2020. "Correction: López-Yerena, A., et al. “Absorption and Intestinal Metabolic Profile of Oleocanthal in Rats” Pharmaceutics 2020, 12, 134" Pharmaceutics 12, no. 12: 1220. https://doi.org/10.3390/pharmaceutics12121220

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop